Loading...
In April 2026, the U.S. FDA approved orforglipron (Foundayo) for the treatment of obesity and overweight in conjunction with a reduced-calorie diet and increased physical activity.
Orforglipron is the second oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of obesity, joining semaglutide. This small nonpeptide molecule has high bioavailability and can be taken with or without food.
Two industry-sponsored randomized trials led to the approval of orforglipron. In both trials, participants had a mean body weight of ≈103 kg at baseline and were randomized to receive one of three orforglipron doses (6, 12, or 36 mg daily after titration) or placebo.
One trial involved 3100 people without diabete…